Diabetes Risk Education and Communication Trial (DiRECT) for Primary Care Patients with Prediabetes

针对初级保健糖尿病前期患者的糖尿病风险教育和沟通试验 (DiRECT)

基本信息

项目摘要

Project Summary Large randomized trials have found that intensive lifestyle interventions (ILI) and metformin are safe and effective treatment options for preventing diabetes among adults with prediabetes. However, these treatments are rarely used, and little existing research has focused on patient-centered approaches for promoting their use. A large body of evidence suggests that risk communication interventions are a promising method for motivating patients to adopt diverse preventive health behaviors. But this approach has not been definitively studied in the context of diabetes prevention. Therefore, the content, structure, and process for communicating diabetes risk to adults with prediabetes is not known. We plan to address this critical knowledge gap by developing and pilot testing the Diabetes Risk Education and Communication Trial (DiRECT) intervention among primary care patients with prediabetes. This novel intervention, delivered by medical assistants before patients’ routinely scheduled office visits, consists of the following 3 components intended to promote initiation of ILI and metformin: 1) a prediabetes decision aid focused on diabetes risk and treatment options for preventing diabetes; 2) a “think aloud” exercise; and 3) formulating a preliminary treatment plan. Previous studies report that medical assistants can improve uptake of some preventive health services in primary care, which may also be true for ILI and metformin. We will test this hypothesis by completing the following specific aims. In Aim 1, we will develop the DiRECT intervention using materials that our group has created and pilot tested in the target population. We will engage an Expert Advisory Panel of stakeholders in diabetes prevention, who will help develop the intervention so that can be widely disseminated if found to be effective. Aim 2 will evaluate the effects of the DiRECT intervention on patients’ perceived risk of developing diabetes and their intention to adopt treatment, in addition to other factors that may impact treatment decisions. Aim 3 is a pilot randomized trial of DiRECT vs. usual care in 80 primary care patients with prediabetes (40 in each arm). This pilot pragmatic trial will estimate the preliminary effects of DiRECT on the following 3-month outcomes: initiation of ILI and/or metformin (primary); adherence to these treatment(s); and weight loss. We will also examine the intervention’s acceptability, impact on clinical workflows, and costs. We hypothesize that the empirically developed DiRECT intervention will improve the accuracy of participants’ risk perceptions and increase their initiation of treatments to prevent diabetes. This study will be conducted in a large community health center, in which 90% of patients with prediabetes are racial/ethnic minorities and 83% live in poverty. Our proposal is responsive to PAR-15-158 by: 1) including a low- income, diverse population; 2) using medical assistants, a workforce that is ubiquitous and therefore scalable to most primary care settings; and 3) leveraging an existing data infrastructure to pragmatically assess participants’ eligibility and collect their clinical data.
项目摘要 大型随机试验发现,强化生活方式干预(ILI)和二甲双胍是安全的, 预防糖尿病前期成人糖尿病的有效治疗选择。然而,这些治疗 很少使用,并且现有的研究很少关注以患者为中心的方法来促进其使用。 大量的证据表明,风险沟通干预是一种很有前途的激励方法。 患者采取多种预防性健康行为。但这种方法尚未得到明确的研究, 预防糖尿病的背景。因此,沟通糖尿病风险的内容、结构和过程 对糖尿病前期成年人的影响尚不清楚。我们计划通过开发和试点来解决这一关键的知识差距 在初级保健中测试糖尿病风险教育和沟通试验(DiRECT)干预措施 糖尿病前期患者。这种新的干预措施,由医疗助理在患者例行检查之前提供, 计划的门诊访视包括以下3个部分,旨在促进ILI和二甲双胍的启动: 1)糖尿病前期决策辅助工具,重点关注糖尿病风险和预防糖尿病的治疗方案; 2)“思考” 3)制定初步治疗方案。先前的研究报告称, 可以提高初级保健中一些预防性卫生服务的利用率,这对ILI也可能是如此, 二甲双胍。我们将通过完成以下具体目标来检验这一假设。在目标1中,我们将开发 直接干预使用的材料,我们的小组已经创建和试点测试的目标人群。我们将 聘请专家咨询小组的利益相关者在糖尿病预防,谁将帮助制定干预措施 以便在发现有效时广为传播。目标2将评估DireCT的效果 干预患者对患糖尿病风险的感知和他们接受治疗的意愿,此外, 其他可能影响治疗决策的因素。目的3是一项比较DiRECT与常规治疗的初步随机试验 在80例糖尿病前期初级保健患者中(每组40例)。这一务实的试点试验将估计 DiRECT对以下3个月结局的初步影响:开始ILI和/或二甲双胍(主要); 坚持这些治疗;和体重减轻。我们还将研究干预的可接受性、影响 临床工作流程和成本。我们假设,经验开发的DIRECT干预将改善 参与者风险认知的准确性,并增加他们开始治疗以预防糖尿病。这 研究将在一个大型社区卫生中心进行,其中90%的糖尿病前期患者是 少数民族和83%的人生活在贫困中。我们的建议是响应PAR-15-158:1)包括低- 收入,不同的人口; 2)使用医疗助理,这是一个无处不在的劳动力,因此可以扩展到 大多数初级保健环境;以及3)利用现有的数据基础设施来务实地评估参与者的 并收集其临床数据。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Matthew James O'Brien其他文献

Social Vulnerability and National Diabetes Prevention Program Recognition Status
社会脆弱性与国家糖尿病预防计划认可状况
  • DOI:
    10.1016/j.amepre.2024.08.018
  • 发表时间:
    2025-01-01
  • 期刊:
  • 影响因子:
    4.500
  • 作者:
    Taynara Formagini;Daphnee Rodriguez;Ariba Rezwan;Jeanean B. Naqvi;Matthew James O'Brien;Boon Peng Ng
  • 通讯作者:
    Boon Peng Ng

Matthew James O'Brien的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Matthew James O'Brien', 18)}}的其他基金

Behavioral Nudges for Diabetes Prevention (BEGIN) Trial in Primary Care
初级保健中的糖尿病预防行为推动 (BEGIN) 试验
  • 批准号:
    10259680
  • 财政年份:
    2020
  • 资助金额:
    $ 24万
  • 项目类别:
Behavioral Nudges for Diabetes Prevention (BEGIN) Trial in Primary Care
初级保健中的糖尿病预防行为推动 (BEGIN) 试验
  • 批准号:
    10630098
  • 财政年份:
    2020
  • 资助金额:
    $ 24万
  • 项目类别:
Behavioral Nudges for Diabetes Prevention (BEGIN) Trial in Primary Care
初级保健中的糖尿病预防行为推动 (BEGIN) 试验
  • 批准号:
    10438843
  • 财政年份:
    2020
  • 资助金额:
    $ 24万
  • 项目类别:
Prevent Diabetes Mellitus (PreDM) Clinical Decision Support Intervention in Community Health Centers
社区卫生中心预防糖尿病 (PreDM) 临床决策支持干预
  • 批准号:
    9767757
  • 财政年份:
    2018
  • 资助金额:
    $ 24万
  • 项目类别:
Promotora Intervention for Metabolic and MentalHealth (PRIME2)
Promotora 代谢和心理健康干预 (PRIME2)
  • 批准号:
    9244422
  • 财政年份:
    2017
  • 资助金额:
    $ 24万
  • 项目类别:
Improving Diabetes Risk Assessment and Screening in Minority-Predominant Community Health Center Patients
改善以少数民族为主的社区卫生中心患者的糖尿病风险评估和筛查
  • 批准号:
    9355174
  • 财政年份:
    2016
  • 资助金额:
    $ 24万
  • 项目类别:
Promotora-Led Intervention to Promote Weight Loss in Latinas at-risk for Diabetes
Promotora 主导的干预措施促进有糖尿病风险的拉丁裔减肥
  • 批准号:
    8847322
  • 财政年份:
    2012
  • 资助金额:
    $ 24万
  • 项目类别:
Promotora-Led Intervention to Promote Weight Loss in Latinas at-risk for Diabetes
Promotora 主导的干预措施促进有糖尿病风险的拉丁裔减肥
  • 批准号:
    9057534
  • 财政年份:
    2012
  • 资助金额:
    $ 24万
  • 项目类别:
Promotora-Led Intervention to Promote Weight Loss in Latinas at-risk for Diabetes
Promotora 主导的干预措施促进有糖尿病风险的拉丁裔减肥
  • 批准号:
    8496773
  • 财政年份:
    2012
  • 资助金额:
    $ 24万
  • 项目类别:
Promotora-Led Intervention to Promote Weight Loss in Latinas at-risk for Diabetes
Promotora 主导的干预措施促进有糖尿病风险的拉丁裔减肥
  • 批准号:
    8663252
  • 财政年份:
    2012
  • 资助金额:
    $ 24万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了